Microphysiological Neurovascular Barriers to Model the Inner Retinal Microvasculature
- PMID: 35207637
- PMCID: PMC8876566
- DOI: 10.3390/jpm12020148
Microphysiological Neurovascular Barriers to Model the Inner Retinal Microvasculature
Abstract
Blood-neural barriers regulate nutrient supply to neuronal tissues and prevent neurotoxicity. In particular, the inner blood-retinal barrier (iBRB) and blood-brain barrier (BBB) share common origins in development, and similar morphology and function in adult tissue, while barrier breakdown and leakage of neurotoxic molecules can be accompanied by neurodegeneration. Therefore, pre-clinical research requires human in vitro models that elucidate pathophysiological mechanisms and support drug discovery, to add to animal in vivo modeling that poorly predict patient responses. Advanced cellular models such as microphysiological systems (MPS) recapitulate tissue organization and function in many organ-specific contexts, providing physiological relevance, potential for customization to different population groups, and scalability for drug screening purposes. While human-based MPS have been developed for tissues such as lung, gut, brain and tumors, few comprehensive models exist for ocular tissues and iBRB modeling. Recent BBB in vitro models using human cells of the neurovascular unit (NVU) showed physiological morphology and permeability values, and reproduced brain neurological disorder phenotypes that could be applicable to modeling the iBRB. Here, we describe similarities between iBRB and BBB properties, compare existing neurovascular barrier models, propose leverage of MPS-based strategies to develop new iBRB models, and explore potentials to personalize cellular inputs and improve pre-clinical testing.
Keywords: 3D models; blood-neural barriers; disease modeling; inner blood-retinal barrier; microphysiological systems; neurovascular unit; organ-on-a-chip.
Conflict of interest statement
T.L.M., C.B., R.V. and H.R. are employees of F. Hoffmann-La Roche Ltd. R.K. is co-founder of AIM Biotech, and receives research support from F. Hoffmann-La Roche Ltd., AbbVie, Amgen, Glaxo-Smith-Kline, Novartis, and Boehringer Ingelheim.
Figures
References
-
- Chen J., Liu C.-H., Sapieha P. Retinal Vascular Development. In: Stahl A., editor. Anti-Angiogenic Therapy in Ophthalmology. Springer International Publishing; Cham, Switzerland: 2016. pp. 1–19.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
